A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Clinical trial NCT06140836 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06140836
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-21
- Primary completion
- 2026-03-13
- Enrollment
- 190
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.